I am looking for help with this Final Paper (8-10 pages) Please make this original, I have attached the instructions as well as the mergent info and website that I have to use forthis paper.

Johnson & Johnson (NYS: JNJ) Business Summary Johnson & Johnson is a holding company. Through its subsidiaries, Co. is engaged in the research and development, manufacture and sale of a range of products in the health care field. Co. is organized into three business segments: Consumer, which is include a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women's health and wound care markets. Pharmaceutical, which is focused on five therapeutic areas: immunology, infectious diseases and vaccines, neuroscience, oncology, and cardiovascular and metabolic diseases. Medical Devices, which is include products used in the orthopaedic, surgery, cardiovascular, diabetes care and vision care fields. Pricing Summary Time Period: 1 week Close Volume 52 Week High/Low : % Price Change (100 Days) : 200-Day Moving Avg. : Company News 5:04AM, 16 September 2016 Toronto has the right recipe for innovation - Toronto Star 9:16PM, 15 September 2016 - New Lawsuit Ties Perineal Use of Talcum Powder to Uterine Cancer - Injury Lawyer News 8:49PM, 15 September 2016 Global healthcare companies seek to bet on Indian startups for fresh start - The Economic Times 2:51PM, 15 September 2016 Johnson & Johnson Launches New Skin Care Brand In China - China Retail News 11:00AM, 15 September 2016 Multi-plaintiff Suit Filed Against Johnson & Johnson As Talcum Powder Lawsuit Numbers Climb Press Release - Digital Journal - DigitalJournal 10:53AM, 15 September 2016 Health concerns over talc continue as U.S. courts sift through evidence - The Legal Examiner 10:33AM, 15 September 2016 China Mengniu Dairy : Announcements and Notices Change of Directors and Chief Executive Officer; Change of Composition of Board Committees - 4-Traders 10:30AM, 15 September 2016 - A Sign of Progress In Xarelto Lawsuit Cases As Case Management Orders Are Given - DigitalJournal 9:57AM, 15 September 2016 Roche to beat Novartis, Pfizer to pharma throne by 2022 as industry passes $1T mark Yesterda y 118.63 5814900 5 Days 125.40 - 91.00 2.44 115.74 30 Days 118.23 121.31 N/A 10442368 - FiercePharma 9:49AM, 15 September 2016 Growing pains - The Economist Corporate Events Earnings Announcement Data - July 14 2015 Conference Call Announcements July 14 2015 Earnings Announcement Data - April 14 2015 Earnings Announcement Data - April 14 2015 Conference Call Announcements April 14 2015 Board Meeting Announcements April 23 2015 Earnings Announcement Data January 20 2015 Event Type: Company Meeting Meeting Type: Investor Conference Annoucements - Date: September 27 2016 Title: Johnson & Johnson Investor Conference Description: Sachs Associates - Annual Biotech in Europe Forum, Basel, Switzerland. More details at: http://www.sachsforum.com/16thannual-biotech-in-europe-investorforum.html Event Type: Company Meeting Meeting Type: Investor Conference Annoucements - Date: September 14 2016 Title: Johnson & Johnson Investor Conference Description: Nordic Life Science Days, Stockholm, Sweden. More details at: http://www.nlsdays.com/ Event Type: Company Meeting Meeting Type: Investor Conference Annoucements - Date: September 08 2016 Title: Johnson & Johnson Investor Conference Description: Wells Fargo - Health Care Conference, Boston, United States. More details at: https://www.wellsfargoresearch.com/ Conferences Event Type: Company Meeting Meeting Type: Conference Call Annoucements - Date: July 19 2016 Title: Johnson & Johnson Q2 Earnings 2016 - Conference Call Description: Johnson & Johnson Conference Call and Webcast Speakers: Alex Gorsky, Chairman and Chief Executive Officer, Dominic Caruso, Executive Vice President, Chief Financial Officer and Louise Mehrotra, Vice President, Investor Relations - Dial In: 877-869-3847 Int Dial In: 201-689-8261 - Webcast: www.investor.jnj.com - Replay Dial In: 877-660-6853 - Replay Passcode: 13639782 - Int Replay Dial In: 201612-7415 - Int Replay Passcode: 13639782 - Replay Webcast: www.investor.jnj.com Speakers: Alex Gorsky, Chairman and Chief Executive Officer, Dominic Caruso, Executive Vice President, Chief Financial Officer and Louise Mehrotra, Vice President, Investor Relations Webcast_URL: www.investor.jnj.com Call Dial Number: 877-869-3847 Call International Dial Number: 877-8693847 Contact Name: Louise Mehrotra Contact Telephone: +1 732 524 6491 Contact Email: mhe@concn.jnj.com Event Type: Company Results Result Type: Earning Annoucement Date Date: July 19 2016 Title: Johnson & Johnson Q2 Earnings 2016 Description: Johnson & Johnson Q2 Earnings 2016 (Before Market) Result Period: 2(nd) Quarter Market Status: before market (Event Status: confirmed) Event Type: Company Meeting Meeting Type: Webcast Annoucements - Date: July 07 2016 Title: Johnson & Johnson Web Cast Description: Johnson & Johnson Web Cast, Janssen and Johnson & Johnson to Provide Webcast Presentation on Phase 3 data for DARZALEX (daratumumab) and the Janssen Immuno-oncology Strategy and Portfolio - Speakers: Pre-recorded Webcast: Peter F. Lebowitz, MD, PhD, Global Therapeutic Area Head of Oncology for Janssen R&D Webcast: www.investor.jnj.com Speakers: Pre-recorded Webcast: Peter F. Lebowitz, MD, PhD, Global Therapeutic Area Head of Oncology for Janssen R&D Webcast_URL: www.investor.jnj.com Contact Name: Louise Mehrotra Contact Telephone: +1 732 524 6491 Contact Email: mhe@concn.jnj.com Event Type: Company Meeting Meeting Type: Industry Conference Annoucements - Date: June 18 2016 Title: Johnson & Johnson - Industry Conference Description: Cannes Lions 2016, Cannes, France. More details at: https://www.canneslions.com/ Key Executives Alex Gorsky Chairman,Chief Executive Officer Dominic Caruso Vice President,Chief Financial Officer Peter Fasolo Vice President Michael Ullmann Vice President,General Counsel Paulus Stoffels Chief Scientific Officer Key Financials (In USD as of 07/03/2016) Age 55 Salary 1613462 57 Salary 922577 52 Salary 534769 57 Salary 645385 53 Salary 1158385 Age Age Age Age Income Statement Revenue Net Income EPS from Continuing Operations EPS - Net Income - Diluted Revenue per Share 7.1E+010 1.5E+010 5.32 5.32 25.82 Balance Sheet Total Assets Total Liabilities Shareholders' Equity Total Assets per Share Net Assets per Share ### 6.7E+010 7.2E+010 51.07 26.47 Cash Flows Cash from Operations Cash from Investing Cash from Financing Capital Expenditures Cash Flow per Share 1.8E+010 -3E+009 -7E+009 3.6E+009 6.43 Evaluation of Corporate Performance The Final Paper will involve applying the concepts learned in class to an analysis of a company using data from its annual report. Using the concepts from this course, you will analyze the strengths and weaknesses of the company and write a report either recommending or not recommending purchase of the company stock. Research Tip: The \"Mergent\" database in the Ashford University Library contains company profiles and financial information for publicly traded companies and their competitors. To access this database enter the Ashford Library and select \"Find Articles and More\" in the top menu panel. Next, select \"Databases A-Z\" and go to section \"M\" for \"Mergent\". For help with using Mergent, use Mergent Online Quick Tips. For help with reading an annual report access this handy guide from Money Chimp. The completed report should include: An introduction to the company, including background information. A complete and thorough financial statement review. Pro Forma financial statements (Balance Sheet and Income Statement) for the next fiscal year, assuming a 10 percent growth rate in sales and Cost of Goods Sold (COGS) for the next year. Complete ratio analysis for the last fiscal year using at least two ratios from each of the following categories: o Liquidity o Financial leverage o Asset management o Profitability o Market value o Debt o Per-Share o Measures of relative value (P/E, P/B) o Activity o Cash Flow A calculation of Return on Equity (ROE) using the DuPont system. Assessment of management performance by calculating Economic Value Added (EVA). A synopsis of your findings, including your recommendations and rationale for whether or not to purchase stock from this company. Evaluate the financial risks associated with operating internationally. If your chosen company does not operate internationally, evaluate what the financial risks could be if they were to expand internationally. Must be eight to ten double-spaced pages in length (not including title and references pages) and formatted according to APA style as outlined in the Ashford Writing Center